Financing led by new Investors Fåhraeus Startup and Growth and EIC Fund HELSINKI, 3rd February 2025. Aplagon, a clinical stage biopharmaceutical company developing a first-in-class therapeutic for thrombo-inflammatory diseases, known as APAC, a heparin proteoglycan mimetic with antiplatelet and anticoagulant effects, announced today it has closed a EUR 7 million financing. The funding round was […]

HELSINKI, November 16, 2022. Aplagon Oy (Aplagon), the Finnish pharmaceutical development company developing first-in-class vasculoprotective antithrombotic agents (APACs) to treat vascular injury related blood vessel occlusions and tissue damage, today announced that it had signed an EIC Accelerator grant agreement (Grant Agreement) with the European Innovation Council and SMEs Executive Agency (EISMEA). Under the Grant […]

HELSINKI, June 7, 2022. Aplagon Oy (“Aplagon”), the Finnish pharmaceutical development company developing first-in-class vasculoprotective antithrombotic agents to treat vascular injury related blood vessel occlusions and tissue damage, today announced that its lead pharmaceutical agent, APAC, has been administered for the first time in a clinical study. The Phase 1 clinical study is primarily intended […]

HELSINKI, May 28, 2021. Aplagon Oy (“Aplagon”), the Finnish pharmaceutical development company developing first-in-class vasculoprotective antithrombotic compounds to treat vascular injury related blood vessel occlusions and tissue damage, today announced the closing of a EUR 2.2 million funding round. The fundraise was arranged in collaboration with Invesdor Group and was oversubscribed. These funds increase the […]